Stay updated on Capmatinib & Spartalizumab vs Docetaxel in NSCLC Clinical Trial
Sign up to get notified when there's something new on the Capmatinib & Spartalizumab vs Docetaxel in NSCLC Clinical Trial page.

Latest updates to the Capmatinib & Spartalizumab vs Docetaxel in NSCLC Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedA new page revision 'Revision: v3.3.3' was added, and the 'HHS Vulnerability Disclosure' link along with the earlier 'Revision: v3.3.2' label were removed.SummaryDifference0.1%

- Check20 days agoNo Change Detected
- Check27 days agoNo Change Detected
- Check34 days agoChange DetectedThe revision label at the bottom of the page updated from v3.3.1 to v3.3.2, which is a UI/version detail and does not affect study data or navigation. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check42 days agoChange DetectedThe record history now includes Revision: v3.3.1 and removes Revision: v3.2.0. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check49 days agoChange DetectedA government funding/status notice that previously appeared on the page has been removed; the overall history content remains unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%

- Check63 days agoChange DetectedNew screenshot shows the same version history entries with only minor visual adjustments to headers and spacing; no core data or version entries were added or removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check92 days agoChange DetectedMajor update: new operating-status notice and a v3.2.0 version release, replacing the prior v3.1.0.SummaryDifference10%

Stay in the know with updates to Capmatinib & Spartalizumab vs Docetaxel in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Capmatinib & Spartalizumab vs Docetaxel in NSCLC Clinical Trial page.